Skip to main content
OpenTrials
Completed

NCT Number: NCT01825044

Copenhagen Head Injury Ciclosporin (CHIC) Study

This is an open label study on the pharmacokinetics and safety of ciclosporin in patients with severe traumatic brain injury, who require intensive care unit admission and monitoring of intracranial pressure via a ventricular catheter. 20 patients will be screened, and subsequently enrolled after clinical stabilisation. Thereafter, patients will receive 2.5 mg/kg bolus dose infusion of ciclosporin, followed by either 5 mg/kg/day or 10 mg/kg/day of ciclosporin as continuous infusion for 5 days+3 days monitoring at the intensive care unit. After an additional 30 days, a follow-up phone call will be made to the patient, or the patient's nursing staff, checking patient status and serious adverse events. The two dose levels will be investigated in 10 patients each, starting with the lower dose level for the first 10 patients. Patients will have samples of blood and cerebrospinal fluid drawn at pre-defined time points during the study for pharmacokinetic assessment and evaluation of biomarkers. Bedside monitoring with microdialysis and brain tissue oxygenation will be performed. The safety monitoring includes nephrotoxicity, hepatotoxicity, monitoring of intracranial pressure (ICP), infections monitoring and adverse events collection and reporting.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Dept. of Neurosurgery, Rigshospitalet, University of Copenhagen

Copenhagen, 2100, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients, age between 18 and 75 years, inclusive.
  • Requirement for Intensive Care Unit (ICU) admission and clinical indication for External Ventricular Drainage (EVD) and Intracranial Pressure (ICP) monitoring.
  • Evidence of non-penetrating severe TBI, confirmed by history and abnormalities consistent with a non-penetrating trauma on computerised tomography (CT) scan upon admission.
  • Clinical examination with post-resuscitation Glasgow Coma Scale (GCS) of 4-8, inclusive.
  • Hemodynamically stable after resuscitation (systolic blood pressure (SBP) >100 mm Hg).
  • Informed consent for participation waived: obtained by two independent physicians and subsequently, the patient's Legally Acceptable Representative (LAR) and General Practitioner (GP). If GP is unavailable, the Danish Health and Medicines Authority can give consent together with the LAR.

Exclusion criteria

  • Bilaterally fixed dilated pupils.
  • Penetrating traumatic brain injury.
  • Spinal cord injury.
  • Pure epidural haematoma.
  • Currently developed, known or a medical history of renal disorder, significant renal failure, or high risk renal failure, defined as:
  • Serum creatinine ≥ 1.5 x upper limit of normal (ULN).
  • Pre-existing chronic renal failure with estimated glomerular filtration rate (eGFR)< 60 ml/min/1.73m2 estimated by the simplified Modification of Diet in Renal Disease (MDRD) Study formula.
  • Major rhabdomyolysis with serum creatine kinase > 5,000 IU/L.
  • Renal injury resulting in loss of a kidney (either due to direct trauma or ischaemia).
  • Vascular injury with renal ischaemia likely to cause an episode of acute renal failure.
  • Any history of renal replacement therapy.
  • Known or a medical history of hepatic disease.
  • Prolonged and/or uncorrectable hypoxia, as judged by the investigator (PaO< 60 mmHg) or hypotension (SBP< 90 mmHg) upon admission.
  • Suspected or confirmed pregnancy (positive urine sample,followed by confirmational serum human chorionic gonadotropin (HCG) pregnancy test).
  • Immunosuppression due to drugs (for ex. ciclosporin) or disease (e.g. human immunodeficiency virus (HIV), malignancy).
  • Known or a medical history of serious chronic viral or fungal infection.
  • Known or a medical history of active mycobacterial infection or antituberculous treatment.
  • Known or a medical history of any allergic reactions and/or anaphylactic reactions towards ciclosporin, egg, peanuts or soya-bean proteins.
  • Ongoing preinjury therapy with any of these drugs:

rosuvastatin, tacrolimus, Hypericum perforatum (St.John´s Wort; a herbal dietary supplement), stiripentol, aliskiren, bosentan, diltiazem, verapamil and antiepileptics.

  • Participation in other clinical trials.
  • Any significant disease or disorder including abnormal laboratory tests which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study

Treatment and study plan

NeuroSTAT 5 mg/kg/day

Drug

Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion

Other names: Ciclosporin 5 mg/kg/day

NeuroSTAT 10 mg/kg/day

Drug

Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion

Other names: Ciclosporin 10 mg/kg/day

Primary outcomes

  1. Non-compartmental analysis of pharmacokinetics (PK) of Ciclosporin in whole blood

    Time frame: Prespecified timepoints during 8 days (PK)

    Peak Plasma Concentration (Cmax) of Ciclosporin and Area under the blood concentration versus time curve (AUC) of Ciclosporin. This will characterise the pharmacokinetic profile of the two chosen dosing regimens of ciclosporin in severe Traumatic Brain Injury (TBI) patients.

  2. Incidence of adverse events

    Time frame: 38 days

    Including:

    • Ciclosporin levels in whole blood.
    • Markers of nephrotoxicity: plasma creatinine plasma Cystatin-C and blood urea nitrogen.
    • Markers of hepatotoxicity: prothrombin time (PT), aspartate transaminase (AST), alanine transaminase (ALT) and bilirubin.
    • Intracranial Pressure (ICP)
    • Assessment of infections: according to standard procedures at intensive care unit.

Secondary outcomes

  1. Ciclosporin levels in cerebrospinal fluid (CSF)

    Time frame: Prespecified timepoints during 8 days

    The CSF samples will be drawn from the EVD-catheter at the same time points as in blood to document central nervous system penetration of ciclosporin

  2. Safety biomarkers for nephrotoxicity

    Time frame: Measured at prespecified timepoints during 8 days

    Kidney Injury Molecule (KIM)-1, creatinine and Cystatin-C in urine samples

Other outcomes

  1. Electroencephalography (EEG).

    Time frame: During 8 days

    The background pattern will be interpreted and analysed by an EEG program. The aim is to find evidence if EEG analyses could be used to predict clinical outcome.

  2. Biomarkers of brain injury in brain tissue

    Time frame: Measured at prespecified timepoints during 8 days

    Microdialysis in the most and least traumatised side pre-treatment and every second hour until the end of day 8

  3. Brain tissue oxygen

    Time frame: During 8 days

    Continuously (every 5th second) measured directly using an indwelling probe.

Sponsors and collaborators

Lead sponsor

NeuroVive Pharmaceutical AB

Industry

Registry information

Official study title

An Open-label, Uncontrolled Phase II-study to Investigate Pharmacokinetics, Safety and Biomarkers of Effectiveness of NeuroSTAT® (Ciclosporin) in Patients With Severe Traumatic Brain Injury (TBI)

Acronym: CHIC

Important dates

Study start
2013
Primary completion
2017
Study completion
2017
First posted
Apr 5, 2013
Registry last updated
Oct 4, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.